Emerging intravesical therapies for management of nonmuscle invasive bladder cancer

Open Access Journal of Urology

Volumn 2, Issue 1, 2010, Pages 67-84

  Tomaszewski, Jeffrey J ^a   Smaldone, Marc C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

BCG; Intravesical therapy; Invasive; Nonmuscle; Transitional cell carcinoma

Indexed keywords

ADENOVIRUS VECTOR; ALPHA2B INTERFERON; ANTHRACYCLINE; ANTINOPLASTIC AGENT; APAZIQUONE; BCG VACCINE; BROPIRIMINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ETOGLUCID; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; LIPOPLEX; LIPOSOME; MITOMYCIN C; MYCOBACTERIAL CELL WALL COMPLEX; PACLITAXEL; SURAMIN; THROMBOSPONDIN 1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALRUBICIN; VISCUM ALBUM LECTIN;

ANEMIA; BLADDER CANCER; BONE MARROW SUPPRESSION; CANCER INCIDENCE; CANCER INHIBITION; CANCER INVASION; CANCER RECURRENCE; CLINICAL TRIAL; CYSTECTOMY; DRUG RESPONSE; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; HYPERTHERMIC THERAPY; KIDNEY DISEASE; LEUKOPENIA; METABOLIC DISORDER; MICTURITION DISORDER; NEUROLOGIC DISEASE; PATIENT SELECTION; PHOTODYNAMIC THERAPY; RECURRENCE RISK; REVIEW; TRANSITIONAL CELL CARCINOMA; UNSPECIFIED SIDE EFFECT;

EID: 77953368152     PISSN: None     EISSN: 11791551     Source Type: Book Series    
DOI: None     Document Type: Review

References (146)

1. Ries L, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005. http://seer.cancer.gov/csr/1975_2005/.
2. Cancer Facts and Figures 2007. Atlanta: American Cancer Society; 2008.
3. Fleshner NE, Herr HW, Stewart AK, Murphy GP, Mettlin C, Menck HR. The National Cancer Data Base report on bladder carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1996 Oct 1;78(7):1505-1513.
4. Kurth KH, Bouffioux C, Sylvester R, van der Meijden AP, Oosterlinck W, Brausi M. Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group. Eur Urol. 2000;37 Suppl 3:1-9.
5. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006 Mar;49(3): 466-465; discussion 475-467.
6. Smaldone MC, Gayed BA, Tomaszewski JJ, Gingrich JR. Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer. Minerva Urol Nefrol. 2009 Jun;61(2):71-89.
7. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007 Dec;178(6):2314-2330.
8. Avritscher EB, Cooksley CD, Grossman HB, et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology. 2006 Sep;68(3):549-553.
9. Smaldone MC, Casella DP, Welchons DR, Gingrich JR. Investigational therapies for non-muscle invasive bladder cancer. Expert Opin Investig Drugs. Mar; 19(3):371-383.
10. Zaharoff DA, Hoffman BS, Hooper HB, et al. Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12. Cancer Res. 2009 Aug 1;69(15):6192-6199.
11. Den Otter W, Dobrowolski Z, Bugajski A, et al. Intravesical interleu-kin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients. J Urol. 1998 Apr;159(4):1183-1186.
12. Weiss GR, O'Donnell MA, Loughlin K, Zonno K, Laliberte RJ, Sherman ML. Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder. J Immunother. 2003 Jul-Aug;26(4):343-348.
13. Glazier DB, Bahnson RR, McLeod DG, von Roemeling RW, Messing EM, Ernstoff MS. Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer: an Eastern Cooperative Oncology Group study. J Urol. 1995 Jul;154(1):66-68.
14. Stravoravdi P, Toliou T, Kirtsis P, et al. A new approach in the management of urothelial tumors using GM-CSF on marker lesions: an ultrastructural and immunohistochemical study on the macrophage population in bladder mucosa. J Interferon Cytokine Res. 1999 Mar;19(3):221-225.
15. Zlotta AR, Van Vooren JP, Denis O, et al. What are the immunologically active components of bacille Calmette-Guerin in therapy of superficial bladder cancer? Int J Cancer. 2000 Sep 15;87(6):844-852.
16. Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M. Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer. Cochrane Database Syst Rev. 2000(4):CD001986.
17. Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002 Nov;168(5):1964-1970.
18. Badalament RA, Herr HW, Wong GY, et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J Clin Oncol. 1987 Mar;5(3):441-449.
19. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000 Apr;163(4):1124-1129.
20. Han RF, Pan JG. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006 Jun;67(6):1216-1223.
21. Witjes JA. What is the optimal BCG dose in non-muscle-invasive bladder cancer? Eur Urol. 2007 Nov;52(5):1300-1302.
22. Rischmann P, Desgrandchamps F, Malavaud B, Chopin DK. BCG intravesical instillations: recommendations for side-effects management. Eur Urol. 2000;37 Suppl 1:33-36.
23. Sylvester RJ, van der Meijden AP, Oosterlinck W, Hoeltl W, Bono AV. The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol. 2003 Oct;44(4):423-428.
24. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003 Jan;169(1):90-95.
25. van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol. 2003 Oct;44(4):429-434.
26. Lebret T, Bohin D, Kassardjian Z, et al. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. J Urol. 2000 Jan;163(1):63-67.
27. Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E, et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol. 2005 Oct;174(4 Pt 1):1242-1247.
28. Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev. 2003(3):CD003231.
29. Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004 Mar;93(4):485-490.
30. Bohle A, Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology. 2004 Apr;63(4):682-686; discussion 686-687.
31. Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus calmetteguerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol. 2005 Jul;174(1):86-91; discussion 91-82.
32. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001 Feb 1;19(3):666-675.
33. Stein JP, Penson DF. The invasive T1 bladder tumor: contemporary issues and rationale for radical cystectomy. Curr Urol Rep. 2008 May;9(3):179-181.
34. Nepple KG, Aubert HA, Braasch MR, O'Donnell MA. Combination of BCG and interferon intravesical immunotherapy: an update. World J Urol. 2009 Jun;27(3):343-346.
35. Portillo J, Martin B, Hernandez R, et al. Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. Urology. 1997 Feb;49(2):187-190.
36. Braasch MR, Bohle A, O'Donnell MA. Risk-adapted use of intravesical immunotherapy. BJU Int. 2008 Nov;102(9 Pt B):1254-1264.
37. O'Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol. 2001 Oct;166(4):1300-1304, discussion 1304-1305.
38. Joudi FN, Smith BJ, O'Donnell MA. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol. 2006 Jul-Aug;24(4):344-348.
39. Gallagher BL, Joudi FN, Maymi JL, O'Donnell MA. Impact of previous bacille Calmette-Guerin failure pattern on subsequent response to bacille Calmette-Guerin plus interferon intravesical therapy. Urology. 2008 Feb;71(2):297-301.
40. Lamm DL, O'Donnell MA. Multicenter randomized comparison of BCG with or without alfa 2b interferon (IFN) and Oncovite (Onc) versus recommended daily allowance (RDA) vitamins during induction and extended 3-week maintenance. J Urol. 2008;179(4 suppl):584 (abstract no. 1705).
41. Witjes WP, Konig M, Boeminghaus FP, et al. Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group. Eur Urol. 1999 Dec;36(6):576-581.
42. Sarosdy MF, Manyak MJ, Sagalowsky AI, et al. Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guerin. Urology. 1998 Feb;51(2):226-231.
43. Sarosdy MF, Tangen CM, Weiss GR, et al. A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guerin for carcinoma in situ of the bladder: a Southwest Oncology Group Study. Urol Oncol. 2005 Nov-Dec;23(6):386-389.
44. Perabo FG, Muller SC. Current and new strategies in immunotherapy for superficial bladder cancer. Urology. 2004 Sep;64(3):409-421.
45. Jurincic-Winkler CD, Metz KA, Beuth J, Klippel KF. Keyhole limpet hemocyanin for carcinoma in situ of the bladder: a long-term follow-up study. Eur Urol. 2000;37 Suppl 3:45-49.
46. Lamm DL, Dehaven JI, Riggs DR. Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies. Eur Urol. 2000;37 Suppl 3:41-44.
47. Flamm J, Donner G, Bucher A, Holtl W, Albrecht W, Havelec L. [Topical immunotherapy (KLH) vs chemotherapy (Ethoglucid) in prevention of recurrence of superficial bladder cancer. A prospective randomized study]. Urologe A. 1994 Mar;33(2):138-143.
48. Kalble T, Mohring K, Ikinger U, Riedasch G, Staehler G. [Intravesical prevention of recurrence of superficial urinary bladder cancer with BCG and KLH. A prospective randomized study]. Urologe A. 1991 Mar;30(2):118-121.
49. Morales A. Evolution of intravesical immunotherapy for bladder cancer: mycobacterial cell wall preparation as a promising agent. Expert Opin Investig Drugs. 2008 Jul;17(7):1067-1073.
50. Filion MC, Lepicier P, Morales A, Phillips NC. Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells. Br J Cancer. 1999 Jan;79(2):229-235.
51. Morales A, Chin JL, Ramsey EW. Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. J Urol. 2001 Nov;166(5):1633-1637; discussion 1637-1638.
52. Morales A, Phadke K, Steinhoff G. Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed. J Urol. 2009 Mar;181(3):1040-1045.
53. Elsasser-Beile U, Ruhnau T, Freudenberg N, Wetterauer U, Mengs U. Antitumoral effect of recombinant mistletoe lectin on chemically induced urinary bladder carcinogenesis in a rat model. Cancer. 2001 Mar 1;91(5):998-1004.
54. Goebell PJ, Otto T, Suhr J, Rubben H. Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial. J Urol. 2002 Jul;168(1):72-75.
55. Elsasser-Beile U, Leiber C, Wolf P, Lucht M, Mengs U, Wetterauer U. Adjuvant intravesical treatment of superficial bladder cancer with a standardized mistletoe extract. J Urol. 2005 Jul;174(1):76-79.
56. Bochner BH. Gene therapy in bladder cancer. Curr Opin Urol. 2008 Sep;18(5):519-523.
57. Shen Z, Shen T, Wientjes MG, O'Donnell MA, Au JL. Intravesical treatments of bladder cancer: review. Pharm Res. 2008 Jul;25(7): 1500-1510.
58. Sachs MD, Ramamurthy M, Poel H, et al. Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. Cancer Gene Ther. 2004 Jul;11(7):477-486.
59. Yamashita M, Rosser CJ, Zhou JH, et al. Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. Cancer Gene Ther. 2002 Aug;9(8):687-691.
60. Connor RJ, Anderson JM, Machemer T, Maneval DC, Engler H. Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens. Urology. 2005 Jul;66(1):224-229.
61. Ramesh N, Ge Y, Ennist DL, et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor-armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res. 2006 Jan 1;12(1):305-313.
62. Fodor I, Timiryasova T, Denes B, Yoshida J, Ruckle H, Lilly M. Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model. J Urol. 2005 Feb;173(2):604-609.
63. Lee CF, Chang SY, Hsieh DS, Yu DS. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vac-cines and interleukin-12 DNA vaccine. J Urol. 2004 Mar;171(3): 1343-1347.
64. Horinaga M, Harsch KM, Fukuyama R, Heston W, Larchian W. Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model. Urology. 2005 Aug;66(2):461-466.
65. Gomella LG, Mastrangelo MJ, McCue PA, Maguire HJ, Mulholland SG, Lattime EC. Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol. 2001 Oct;166(4): 1291-1295.
66. Kuball J, Wen SF, Leissner J, et al. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol. 2002 Feb 15;20(4):957-965.
67. Pagliaro LC, Keyhani A, Williams D, et al. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol. 2003 Jun 15;21(12):2247-2253.
68. Pawinski A, Sylvester R, Kurth KH, et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol. 1996 Dec;156(6):1934-1940, discussion 1940-1931.
69. Lamm DL, Riggs DR, Traynelis CL, Nseyo UO. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol. 1995 May;153(5):1444-1450.
70. Huncharek M, Geschwind JF, Witherspoon B, McGarry R, Adcock D. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol. 2000 Jul;53(7):676-680.
71. Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res. 2001 Jan-Feb;21(1B):765-769.
72. Verweij J, Pinedo HM. Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs. 1990 Oct;1(1):5-13.
73. Mostafid AH, Rajkumar RG, Stewart AB, Singh R. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer. BJU Int. 2006 Mar;97(3):509-512.
74. Huland H, Otto U, Droese M, Kloppel G. Long-term mitomycin C instillation after transurethral resection of superficial bladder carci-noma: influence on recurrence, progression and survival. J Urol. 1984 Jul;132(1):27-29.
75. Allona Moncada A, Garcia Vaquero S, Zuloaga Gomez A, et al. [Preliminary results of a multicenter study with mitomycin C in superficial bladder tumors (Ta, T1)]. Actas Urol Esp. 1988 Sep-Oct;12(5):424-429.
76. Huland H, Otto U. Mitomycin instillation to prevent recurrence of superficial bladder carcinoma. Results of a controlled, prospective study in 58 patients. Eur Urol. 1983;9(2):84-86.
77. Tolley DA, Parmar MK, Grigor KM, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol. 1996 Apr;155(4):1233-1238.
78. Ooterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol. 1993 Apr;149(4):749-752.
79. Bouffioux C, Kurth KH, Bono A, et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol. 1995 Mar;153(3 Pt 2):934-941.
80. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004 Jun;171 (6 Pt 1):2186-2190, quiz 2435.
81. Ali-el-Dein B, Nabeeh A, el-Baz M, Shamaa S, Ashamallah A. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol. 1997 May;79(5):731-735.
82. Koga H, Kuroiwa K, Yamaguchi A, Osada Y, Tsuneyoshi M, Naito S. A randomized controlled trial of short-term versus long-term pro-phylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder. J Urol. 2004 Jan;171(1):153-157.
83. Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guerin (BCG) in patients with non-mus-cle-invasive bladder carcinoma. Eur Urol. 2007 Oct;52(4):1123-1129.
84. Koontz WW Jr, Prout GR Jr, Smith W, Frable WJ, Minnis JE. The use of intravesical thiotepa in the management of non-invasive carcinoma of the bladder. J Urol. 1981 Mar;125(3):307-312.
85. Heney NM, Koontz WW, Barton B, et al. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carci-noma of the bladder: a phase III prospective randomized study. J Urol. 1988 Dec;140(6):1390-1393.
86. Hirao Y, Okajima E, Ozono S, et al. A prospective randomized study of prophylaxis of tumor recurrence following transurethral resection of superficial bladder cancer-intravesical thio-TEPA versus oral UFT. Cancer Chemother Pharmacol. 1992;30 Suppl:S26-S30.
87. Martinez-Pineiro JA, Jimenez Leon J, Martinez-Pineiro L Jr, et al. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a ran-domized prospective study in 202 patients with superficial bladder cancer. J Urol. 1990 Mar;143(3):502-506.
88. Burnand KG, Boyd PJ, Mayo ME, Shuttleworth KE, Lloyd-Davies RW. Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma. Br J Urol. 1976 Feb;48(1):55-59.
89. Byar D, Blackard C. Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer. Urology. 1977 Dec;10(6):556-561.
90. Zincke H, Utz DC, Taylor WF, Myers RP, Leary FJ. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. J Urol. 1983 Mar;129(3):505-509.
91. Prout GR Jr, Koontz WW Jr, Coombs LJ, Hawkins IR, Friedell GH. Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. J Urol. 1983 Oct;130(4):677-680.
92. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997 Nov;15(11):3394-3398.
93. Dalbagni G, Russo P, Sheinfeld J, et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol. 2002 Aug 1;20(15):3193-3198.
94. Gontero P, Casetta G, Maso G, et al. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol. 2004 Sep;46(3):339-343.
95. Bartoletti R, Cai T, Gacci M, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study. Urology. 2005 Oct;66(4):726-731.
96. Mattioli F, Curotto A, Manfredi V, et al. Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study. Anticancer Res. 2005 May-Jun;25(3c):2493-2496.
97. Dalbagni G, Russo P, Bochner B, et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol. 2006 Jun 20;24(18):2729-2734.
98. Addeo R, Caraglia M, Bellini S, et al. Randomized Phase III Trial on Gemcitabine Versus Mytomicin in Recurrent Superficial Bladder Cancer: Evaluation of Efficacy and Tolerance. J Clin Oncol. 2009 Oct 19.
99. Perdona S, Di Lorenzo G, Cantiello F, et al. Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial. Anticancer Drugs. 2009 Oct 24.
100. Witjes JA, Hendricksen K. Intravesical pharmacotherapy for nonmuscle-invasive bladder cancer: a critical analysis of currently avaiable drugs, treatment schedules, and long-term results. Eur Urol. 2008 Jan;53(1):45-52.
101. Patterson AL, Greenberg RE, Weems L, et al. Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. Urology. 2000 Aug 1;56(2):232-235.
102. Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette- Guerin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991 Oct 24;325(17):1205-1209.
103. van der Meijden AP, Brausi M, Zambon V, Kirkels W, de Balincourt C, Sylvester R. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol. 2001 Aug;166(2):476-481.
104. Rajala P, Kaasinen E, Raitanen M, Liukkonen T, Rintala E. Perioperative single dose instillation of epirubicin or interferon- alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study - FinnBladder III long-term results. J Urol. 2002 Sep;168(3):981-985.
105. Liu B, Wang Z, Chen B, et al. Randomized study of single instillation of epirubicin for superficial bladder carcinoma: long-term clinical outcomes. Cancer Invest. 2006 Mar;24(2):160-163.
106. Duchek M, Johansson R, Jahnson S, et al. Bacillus Calmette-Guerin Is Superior to a Combination of Epirubicin and Interferon-alpha2b in the Intravesical Treatment of Patients with Stage T1 Urinary Bladder Cancer. A Prospective, Randomized, Nordic Study. Eur Urol. 2009 Oct 6.
107. Sekine H, Ohya K, Kojima SI, Igarashi K, Fukui I. Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette- Guerin therapy for carcinoma in situ of the bladder. Int J Urol. 2001 Sep;8(9):483-486.
108. Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000 Mar;163(3):761-767.
109. Martin FM, Kamat AM. Definition and management of patients with bladder cancer who fail BCG therapy. Expert Rev Anticancer Ther. 2009 Jun;9(6):815-820.
110. Puri R, Palit V, Loadman PM, et al. Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer. J Urol. 2006 Oct;176(4 Pt 1):1344-1348.
111. Hendricksen K, Gleason D, Young JM, et al. Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer. J Urol. 2008 Jul;180(1):116-120.
112. Jain A, Phillips RM, Scally AJ, Lenaz G, Beer M, Puri R. Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates. Urology. 2009 May;73(5):1083-1086.
113. van der Heijden AG, Moonen PM, Cornel EB, et al. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol. 2006 Oct; 176(4 Pt 1):1349-1353; discussion 1353.
114. Hendricksen K, van der Heijden AG, Cornel EB, et al. Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. World J Urol. 2009 Jun;27(3):337-342.
115. Dimopoulos MA, Bakoyannis C, Georgoulias V, et al. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol. 1999 Nov;10(11):1385-1388.
116. Rangel C, Niell H, Miller A, Cox C. Taxol and taxotere in bladder cancer: in vitro activity and urine stability. Cancer Chemother Pharmacol. 1994;33(6):460-464.
117. McKiernan JM, Masson P, Murphy AM, et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol. 2006 Jul 1;24(19):3075-3080.
118. Laudano MA, Barlow LJ, Murphy AM, et al. Long-term Clinical Outcomes of a Phase I Trial of Intravesical Docetaxel in the Management of Non-Muscle-Invasive Bladder Cancer Refractory to Standard Intravesical Therapy. Urology. 2009 Nov 12.
119. Barlow LJ, McKiernan JM, Benson MC. The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World J Urol. 2009 Jun;27(3):331-335.
120. Le Visage C, Rioux-Leclercq N, Haller M, Breton P, Malavaud B, Leong K. Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer. J Urol. 2004 Mar;171(3):1324-1329.
121. Crew JP, O'Brien T, Bradburn M, et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res. 1997 Dec 1;57(23):5281-5285.
122. Gansler T, Vaghmar N, Olson JJ, Graham SD. Suramin inhibits growth factor binding and proliferation by urothelial carcinoma cell cultures. J Urol. 1992 Sep;148(3):910-914.
123. Fujiyama C, Jones A, Fuggle S, Bicknell R, Cranston D, Harris AL. Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion. Br J Cancer. 2001 Feb;84(4):558-564.
124. Ord JJ, Streeter E, Jones A, et al. Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma. Br J Cancer. 2005 Jun 20;92(12):2140-2147.
125. Lamm DL. Intravesical therapy for superficial bladder cancer: slow but steady progress. J Clin Oncol. 2003 Dec 1;21(23):4259-4260.
126. Au JL, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst. 2001 Apr 18;93(8):597-604.
127. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J. EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder. Eur Urol. 2008 Aug;54(2):303-314.
128. Cliff AM, Heatherwick B, Scoble J, Parr NJ. The effect of fasting or desmopressin before treatment on the concentration of mitomycin C during intravesical administration. BJU Int. 2000 Oct;86(6):644-647.
129. Chen D, Song D, Wientjes MG, Au JL. Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel. Clin Cancer Res. 2003 Jan;9(1):363-369.
130. Grabnar I, Bogataj M, Mrhar A. Influence of chitosan and polycarbophil on permeation of a model hydrophilic drug into the urinary bladder wall. Int J Pharm. 2003 Apr 30;256(1-2):167-173.
131. Hobarth K, Maier U, Marberger M. Topical chemoprophylaxis of superficial bladder cancer with mitomycin C and adjuvant hyaluronidase. Eur Urol. 1992;21(3):206-210.
132. Colombo R, Da Pozzo LF, Lev A, Freschi M, Gallus G, Rigatti P. Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J Urol. 1996 Apr;155(4):1227-1232.
133. Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol. 2003 Dec 1;21(23):4270-4276.
134. van der Heijden AG, Kiemeney LA, Gofrit ON, et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol. 2004 Jul;46(1):65-71; discussion 71-62.
135. Brausi M, Campo B, Pizzocaro G, et al. Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study. Urology. 1998 Mar;51(3):506-509.
136. Di Stasi SM, Giannantoni A, Stephen RL, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol. 2003 Sep;170(3):777-782.
137. Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 2006 Jan;7(1):43-51.
138. Di Stasi SM, Storti L, Giurioli A, et al. Single immediate preoperative instillation of electromotive mitomycin-C plus transurethral resection versus transurethral resection alone versus transurethral resection plus immediate mitomycin-C for pTa bladder tumors: long term results of a prospective randomized trial. J Urol. 2008;179(suppl 4):585 (abstract #1707).
139. Nseyo UO, DeHaven J, Dougherty TJ, et al. Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience. J Clin Laser Med Surg. 1998 Feb;16(1):61-68.
140. Skyrme RJ, French AJ, Datta SN, Allman R, Mason MD, Matthews PN. A phase-1 study of sequential mitomycin C and 5-aminolaevulinic acid-mediated photodynamic therapy in recurrent superficial bladder carcinoma. BJU Int. 2005 Jun;95(9):1206-1210.
141. Berger AP, Steiner H, Stenzl A, Akkad T, Bartsch G, Holtl L. Photo- dynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology. 2003 Feb;61(2):338-341.
142. Ye Z, Chen J, Zhang X, et al. Novel gelatin-adriamycin sustained drug release system for intravesical therapy of bladder cancer. J Tongji Med Univ. 2001;21(2):145-148.
143. Tyagi P, Chancellor MB, Li Z, et al. Urodynamic and immunohistochemical evaluation of intravesical capsaicin delivery using thermosensitive hydrogel and liposomes. J Urol. 2004 Jan;171(1):483-489.
144. Leakakos T, Ji C, Lawson G, Peterson C, Goodwin S. Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers. Cancer Chemother Pharmacol. 2003 Jun;51(6):445-450.
145. Lambert EH, Pierorazio PM, Olsson CA, Benson MC, McKiernan JM, Poon S. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int. 2007 Jul;100(1):33-36.
146. Hautmann RE, Paiss T. Does the option of the ileal neobladder stimulate patient and physician decision toward earlier cystectomy? J Urol. 1998 Jun;159(6):1845-1850.